Interpace Diagnostics Group Stock News

Oppenheimer analyst Kevin DeGeeter assigned a Buy rating to Personalis (PSNL – Research Report) today and set a price target

Utah Medical Products (NASDAQ:UTMD) and Interpace Diagnostics Group (NASDAQ:IDXG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on BioNano Genomics (BNGO – Research

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Celcuity (CELC – Research Report),

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Vascular Biogenics (VBLT – Research Report) yesterday and set a price

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Fate Therapeutics (FATE – Research

Maxim Group analyst Jason McCarthy assigned a Buy rating to Heat Biologics (HTBX – Research Report) today and set a

Maxim Group analyst Jason McCarthy initiated coverage with a Buy rating on Annovis Bio (ANVS – Research Report) today and

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on HTG Molecular Diagnostics (HTGM –

Interpace Diagnostics Group (NASDAQ:IDXG) was upgraded by research analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a research report issued on Wednesday, ValuEngine repo

In a report released yesterday, Kevin DeGeeter from Oppenheimer maintained a Buy rating on BioNano Genomics (BNGO – Research Report),

The

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Armata Pharmaceuticals

Equities analysts expect Interpace Diagnostics Group Inc (NASDAQ:IDXG) to announce earnings of ($1.19) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have ma

Maxim Group analyst Jason McCarthy assigned a Buy rating to Navidea (NAVB – Research Report) today and set a price